# Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

> **NCT00274924** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 100 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** rituximab
- **DRUG:** carboplatin
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **DRUG:** prednisone
- **DRUG:** vincristine

## Key facts

- **NCT ID:** NCT00274924
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-26
- **Primary completion:** 2013-06
- **Final completion:** 2019-03
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274924, "Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00274924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*